- Country: USA
- Summary: Notice of Intent-Inova Fairfax Hospital Biorepository
- UST Ref No: 126677770
- Deadline: 26 Sep 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 25-009982
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
NOTICE OF INTENT (NOI) Inova Fairfax Hospital Biorepository
Product Service Code (PSC): 6640
NAICS Code: 541380
Place of Performance: Bethesda, MD 20892 USA
POTS Number: 25-009982
Description
This is a Notice of Intent, not a request for quotation. No solicitation will be issued, and no quotations will be requested.The National Institutes of Health (NIH) intends to award a fixed-price purchase order for a biorepository to:Inova Fairfax Hospital, Advanced Lung Disease Clinic3300 Gallows Road, Fairfax, VA 22042The establishment of this contract with Inova Fairfax Hospital will provide access to a patient population to develop a biorepository of patients suspected of or diagnosed with Pulmonary Hypertension (PH). The objective is to collect blood samples, demographics, clinical assessments, and outcome data in enrolled subjects. These samples will allow translational research across all the World Health Organization (WHO) PH groups.
Scientific Rationale
Pulmonary Hypertension (PH) is a multifaceted and progressive condition characterized by elevated pulmonary arterial pressure, which can lead to right heart failure and death if untreated. The World Health Organization (WHO) classifies PH into:• Group 1: Pulmonary arterial hypertension (PAH) due to direct pulmonary vascular injury• Group 2: PH related to left-sided heart failure• Group 3: PH from parenchymal lung disease with hypoxemia• Group 4: PH from chronic thromboembolic disease• Group 5: PH with unclear and/or multifactorial mechanismsIn practice, patients with PH are often heterogeneous and present overlapping features that can change over time. Significant overlap between phenotypes makes therapeutic decisions challenging.The data collected will be used to:• Investigate the ability of biomarkers to distinguish between PH groups• Elucidate underlying molecular phenotypes• Predict clinically relevant outcomes• Identify non-invasive biomarkers to track disease pr... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNotice of Intent-Inova Fairfax Hospital Biorepository - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Notice of Intent-Inova Fairfax Hospital Biorepository. This tender is published on USARFP under UST Ref No: 126677770 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-09-26.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
